Simultaneous loss of TOX and TOX2 improves the antitumor potency of TILs, but loss of TOX2 alone is not sufficient to significantly reduce tumor burden, suggesting that, in mouse models, the contribution of TOX2 to exhaustion is weaker compared to TOX (9). The gene discussed is TOX; the disease is neoplasm.